

Medical Science

A study of clinicopathological patterns of renal tumors among a Kurdish population in Kermanshah province, Western Iran

Babak Izadi¹, Somayeh Jalilian², Mazaher Ramezani^{1⊠}, Masoud Sadeghi³, Sedigheh Khazaei¹

[™]Corresponding author

Molecular Pathology Research Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Email: mazaher_ramezani@yahoo.com

Article History

Received: 01 September 2019

Reviewed: 04/September/2019 to 19/October/2019

Accepted: 21 October 2019 Prepared: 24 October 2019

Published: January - February 2020

Citation

Babak Izadi, Somayeh Jalilian, Mazaher Ramezani, Masoud Sadeghi, Sedigheh Khazaei. A study of clinicopathological patterns of renal tumors among a Kurdish population in Kermanshah province, Western Iran. Medical Science, 2020, 24(101), 127-134

Publication License



This work is licensed under a Creative Commons Attribution 4.0 International License.

General Note



Article is recommended to print as color digital version in recycled paper.

ABSTRACT

Introduction: Renal tumor is a serious public health problem which has been steadily increasing and varies in different regions. We purposed to check the clinicopathological features of renal tumors in Kermanshah (west of Iran). Materials and Methods: The



¹Molecular Pathology Research Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

²Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

³Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

population under this cross-sectional study consisted of 172 cases of histologically diagnosed renal tumors. Specimens were obtained from Imam Reza hospital in Kermanshah (west of Iran) between March 2008 and March 2017. Histological reports and frequency of different renal tumors were documented. Results: A total of 172 cases of renal tumors were collected that their mean age was 54.3 years. The frequency of renal cell carcinoma as the most common cell type was found to be 89.5%. The frequency of clear cell renal cell carcinoma (RCC), papillary RCC, and chromophobe RCC were 61%, 19.7%, and 8.2%, respectively. Other tumors included oncocytoma (5.8%), malignant lymphoma (2.3%), squamous cell carcinoma, Wilms tumor (1.2% from each), and sarcomatoid RCC (0.6%). The mean tumor size was 5.2 cm. Conclusions: The differences in the prevalence of renal cancer in the world maybe owing to differences in the distribution of risk factors, socioeconomic levels, early detection, and treatment availability. It is necessary to perform etiological studies to explore the risk factors for renal cancer in this region.

Keywords: Renal neoplasm, Clinicopathological pattern, Kurdish population

1. INTRODUCTION

Cancer is the leading reason of mortality in the world, and the mortality rate is further increasing year by year. The renal tumor is the 13th most common cancer globally in both genders (Chow and Devesa, 2008; Setiawan et al., 2007; Siegel et al., 2013). Malignant tumors of the renal have been reported to account for 2% to 3% of the cancers in adults worldwide (Czene and Hemminki, 2003). The metastatic renal tumor is one of the most treatment-resistant malignancies with a five-year relative survival rate of 12.3% at the time of diagnosis (Sanfilippo et al., 2014). This cancer is one of the public health problems in the USA, in which the incidence of this cancer has been reported in various ethnic groups. There are about 65,000 new cases and about 14,000 deaths from renal cell carcinoma (RCC) each year in the USA (Siegel et al., 2013). Despite multiple studies, many clinicopathological issues about renal tumors remain contentious. The incidence and mortality of renal cancer are different in various countries. Difference between countries is due to the different risk factors according to their lifestyles (Siegel et al., 2013; Chow et al., 2010; Motzeret al., 2017). Smoking, obesity, diet and hypertension are the main risk factors found in epidemiologic studies on the renal tumor. Studies have demonstrated that the developing countries have higher rates of mortality than the developed countries (Znaor et al., 2015). Clear cell RCC (CCRCC) is the most common renal parenchymal malignancy that is followed by papillary and chromophobe RCC (PRCC and CRCC), (Eble et al., 2004). RCC diagnosis accounts for about 3.9% of new cancers. Approximately 70% to 75% of renal tumors reported are of clear cell type. CCRCC is well-known for its metastasis to unusual sites (Eble et al., 2004; Linehan et al., 2003). PRCC is a morphologically, clinically, and genetically distinct subtype and second in frequency to clear cell carcinoma. The importance of RCC in patients is the increased risk of bladder and prostate cancers (Czene and Hemminki, 2003). PRCC frequently contains necrosis (Moch, 2013). CRCC accounts for about 5% of surgically excised renal epithelial neoplasms (Cheng et al., 2009). It has been suggested that liver metastasis is more frequent in CRCC (Moch, 2013). Although the histopathologic subtypes of renal tumor have been shown to be different in clinical features and genetic factors, epidemiological data on subtypes of renal tumor are sparse and have not shown consistent patterns. Furthermore, the pathologic characteristics of renal tumors are important. Pathologic diagnosis can help in the primary treatment, better planning for prevention, and further studies. Therefore, we proposed to check the epidemiology and clinicopathological features of renal tumors in Kermanshah (a city in the west of Iran with a Kurdish population), which will support clinicians to develop better diagnostic and therapeutic methods.

2. MATERIALS AND METHODS

The present study was approved by the Ethics Committee of Kermanshah University of Medical Sciences, Kermanshah, Iran (ethical code: IR.KUMS.REC.1396.420). The population under this cross-sectional study consisted of 172 cases of clinicopathological renal tumors. Samples were obtained from Imam Reza hospital in Kermanshah (Iran) between March 2008 and March 2017. This hospital is the main training center of pathology in the west of Iran. Histological reports were screened for renal tumor. Different renal tumors included malignant tumors (CCRCC, PRCC, CRCC, sarcomatoid RCC (SRCC), malignant lymphoma, and Wilms tumor in children) and benign tumors such as oncocytoma. All cases were registered based on age and gender and histological characteristics, including tumor type, tumor size, capsular invasion, and vascular invasion. These divisions were done according to the National Comprehensive Cancer Network (NCCN) guidelines for patients: (Available online at NCCN.org/patients).

Data were analyzed by SPSS software (version 16.0) using Pearson correlation and chi-square tests to assess the epidemiological and clinicopathological features. P-value < 0.05 was considered to be statistically significant.

3. RESULTS

A total of 172 cases of renal tumors were investigated. The mean age (\pm standard deviation or \pm SD) of the individuals with renal tumors was 54.3 (\pm 15.8) years with minimum and maximum ages of 1 and 84 years, respectively. Among them, 79 samples were women (45.9%) and 93 were men (54.1%). The characteristics of the patients are shown in Table 1.

Table 1 Characteristics of patients with renal tumors (n=172)

Age, year Mean ± SD 54.3 ± 15.8 Range 1-84 Sex Male Male 93 (54.1%) Female 79 (45.9%) Histological type Renal cell carcinoma 154 (89.5%) Oncocytoma 10 (5.8%) Malignant lymphoma 4 (2.3%) Squamous cell carcinoma 2 (1.2%) Wilm's tumor 2 (1.2%) Tumor size, cm Mean ± SD 0.2-21 Range 89 (51.7%)/66 <5.5-10/>10 (38.4%)/17 (9.9%) Laterality Right 74 (46.5%) Left 85 (53.5%) NA 13 Lymph node involvement Yes No 162 (94.2%)	Variable	Value			
Range 1-84 Sex Male 93 (54.1%) Female 79 (45.9%) Histological type Renal cell carcinoma 154 (89.5%) Oncocytoma 10 (5.8%) Malignant lymphoma 4 (2.3%) Squamous cell carcinoma 2 (1.2%) Wilm's tumor 2 (1.2%) Tumor size, cm 5.2 ± 3.4 Mean ± SD 0.2-21 Range 89 (51.7%)/66 < 5.5-10/>10 (38.4%)/17 (9.9%) Laterality Right 74 (46.5%) Left 85 (53.5%) NA 13 Lymph node involvement 10 (5.8%)	Age, year				
Sex Male 93 (54.1%) Female 79 (45.9%) Histological type Renal cell carcinoma Renal cell carcinoma 154 (89.5%) Oncocytoma 10 (5.8%) Malignant lymphoma 4 (2.3%) Squamous cell carcinoma 2 (1.2%) Wilm's tumor 2 (1.2%) Tumor size, cm 5.2 ± 3.4 Mean ± SD 0.2-21 Range 89 (51.7%)/66 <5.5-10/>10 (38.4%)/17 (9.9%) Laterality Right 74 (46.5%) Left 85 (53.5%) NA 13 Lymph node involvement 10 (5.8%)	Mean ± SD	54.3 ± 15.8			
Male 93 (54.1%) Female 79 (45.9%) Histological type Renal cell carcinoma 154 (89.5%) Oncocytoma 10 (5.8%) Malignant lymphoma 4 (2.3%) Squamous cell carcinoma 2 (1.2%) Wilm's tumor 2 (1.2%) Tumor size, cm 5.2 ± 3.4 Mean ± SD 0.2-21 Range 89 (51.7%)/66 <5.5-10/>10 (38.4%)/17 (9.9%) Laterality Right 74 (46.5%) Left 85 (53.5%) NA 13 Lymph node involvement 10 (5.8%)	Range	1-84			
Female 79 (45.9%) Histological type Renal cell carcinoma 154 (89.5%) Oncocytoma 10 (5.8%) Malignant lymphoma 4 (2.3%) Squamous cell carcinoma 2 (1.2%) Wilm's tumor 2 (1.2%) Tumor size, cm Mean ± SD 0.2-21 Range 89 (51.7%)/66 <5.5-10/>10 (38.4%)/17 (9.9%) (9.9%) Laterality Right 74 (46.5%) Left 85 (53.5%) NA 13 Lymph node involvement Yes 10 (5.8%)	Sex				
Histological type Renal cell carcinoma 154 (89.5%) Oncocytoma 10 (5.8%) Malignant lymphoma 4 (2.3%) Squamous cell carcinoma 2 (1.2%) Wilm's tumor 2 (1.2%) Tumor size, cm 5.2 ± 3.4 Mean ± SD 0.2-21 Range 89 (51.7%)/66 <5.5-10/>10 (38.4%)/17 (9.9%) Laterality Right 74 (46.5%) Left 85 (53.5%) NA 13 Lymph node involvement 10 (5.8%)	Male	93 (54.1%)			
Renal cell carcinoma 154 (89.5%) Oncocytoma 10 (5.8%) Malignant lymphoma 4 (2.3%) Squamous cell carcinoma 2 (1.2%) Wilm's tumor 2 (1.2%) Tumor size, cm Mean ± SD 0.2-21 Range 89 (51.7%)/66 <5.5-10/>10 (38.4%)/17 (9.9%) Laterality Right 74 (46.5%) Left 85 (53.5%) NA 13 Lymph node involvement Yes 10 (5.8%)	Female	79 (45.9%)			
Oncocytoma 10 (5.8%) Malignant lymphoma 4 (2.3%) Squamous cell carcinoma 2 (1.2%) Wilm's tumor 2 (1.2%) Tumor size, cm 5.2 ± 3.4 Mean ± SD 0.2-21 Range 89 (51.7%)/66 <5.5-10/>10 (38.4%)/17 (9.9%) (9.9%) Laterality 74 (46.5%) Left 85 (53.5%) NA 13 Lymph node involvement 10 (5.8%)	Histological type				
Malignant lymphoma 4 (2.3%) Squamous cell carcinoma 2 (1.2%) Wilm's tumor 2 (1.2%) Tumor size, cm 5.2 ± 3.4 Mean ± SD 0.2-21 Range 89 (51.7%)/66 <5.5-10/>10 (38.4%)/17 (9.9%) Laterality Right 74 (46.5%) Left 85 (53.5%) NA 13 Lymph node involvement 10 (5.8%)	Renal cell carcinoma	154 (89.5%)			
Squamous cell carcinoma 2 (1.2%) Wilm's tumor 2 (1.2%) Tumor size, cm 5.2 ± 3.4 Mean ± SD 0.2-21 Range 89 (51.7%)/66 <5.5-10/>10 (38.4%)/17 (9.9%) Laterality Right 74 (46.5%) Left 85 (53.5%) NA 13 Lymph node involvement Yes 10 (5.8%)	Oncocytoma	10 (5.8%)			
Wilm's tumor 2 (1.2%) Tumor size, cm 5.2 ± 3.4 Mean ± SD 0.2-21 Range 89 (51.7%)/66 <5.5-10/>10 (38.4%)/17 (9.9%) Laterality Right 74 (46.5%) Left 85 (53.5%) NA 13 Lymph node involvement 10 (5.8%)	Malignant lymphoma	4 (2.3%)			
Tumor size, cm S.2 ± 3.4 Mean ± SD Range 89 (51.7%)/66 <5.5-10/>10 (38.4%)/17 (9.9%) Laterality Right Right 74 (46.5%) Left 85 (53.5%) NA 13 Lymph node involvement Yes 10 (5.8%)	Squamous cell carcinoma	2 (1.2%)			
Mean ± SD Range <5.5-10/>10 Laterality Right Left NA 13 Lymph node involvement Yes 0.2-21 (38.4%)/17 (9.9%) (38.4%)/17 (9.9%) 138.46.5%) 146.5%) 158.5%	Wilm's tumor	2 (1.2%)			
Mean ± SD Range <5.5-10/>10 Laterality Right Left NA 13 Lymph node involvement Yes 0.2-21 (38.4%)/17 (9.9%) (38.4%)/17 (9.9%) 138.46.5%) 146.5%) 158.5%					
Range 89 (51.7%)/66 <5.5-10/>10 (38.4%)/17 (9.9%) Laterality Right 74 (46.5%) Left 85 (53.5%) NA 13 Lymph node involvement Yes 10 (5.8%)	Tumor size, cm	5.2 ± 3.4			
<5.5-10/>10 (38.4%)/17 (9.9%) Laterality Right 74 (46.5%) Left 85 (53.5%) NA 13 Lymph node involvement Yes 10 (5.8%)	Mean ± SD	0.2-21			
Laterality (9.9%) Right 74 (46.5%) Left 85 (53.5%) NA 13 Lymph node involvement Yes 10 (5.8%)	Range	89 (51.7%)/66			
Laterality Right 74 (46.5%) Left 85 (53.5%) NA 13 Lymph node involvement Yes 10 (5.8%)	<5.5-10/>10	(38.4%)/17			
Right 74 (46.5%) Left 85 (53.5%) NA 13 Lymph node involvement Yes 10 (5.8%)		(9.9%)			
Left 85 (53.5%) NA 13 Lymph node involvement Yes 10 (5.8%)	Laterality				
NA 13 Lymph node involvement Yes 10 (5.8%)	Right	74 (46.5%)			
Lymph node involvement Yes 10 (5.8%)	Left	85 (53.5%)			
Yes 10 (5.8%)	NA	13			
` ,	Lymph node involvement				
No 162 (94.2%)	Yes				
	No	162 (94.2%)			
Vascular invasion	Vascular invasion				
Yes 18 (10.5%)	Yes	18 (10.5%)			
No 154 (89.5%)	No	154 (89.5%)			
Capsular invasion	Capsular invasion				
Yes 61 (36.7%)	Yes	61 (36.7%)			
No 105 (63.3%)	No	105 (63.3%)			
NA 6	NA	6			

Abbreviation: NA, not available.

The most prevalent renal tumors in Kermanshah (Iran) between March 2008 and March 2017 were obtained in 2015 (17%), 2016 (14.5%) and 2017(13%), respectively. In this study, the prevalence of the main bulk of tumors was 89.5% (154/172) in RCC. The most common cell type of RCC was CCRCC (61%), followed by PRCC (19.7%) and CRCC (8.2%). Other tumors included oncocytoma (5.8%), malignant lymphoma (2.3%), squamous cell carcinoma, Wilms tumor (each 1.2%), and SRCC (0.6%) (Figure 1).








Figure 1 Prevalence of renal tumor patients based on types

All the renal tumors were divided into different age groups. There was a high rate of renal tumors in the age group of 50-70 years. A similar pattern of age distribution was observed in all subtypes of renal cancers (Figure 2).

Table 2 Comparison of distribution of renal cell carcinoma (RCC) types by variables

Variable	Clear cell carcinoma (n=105)	Papillary carcinoma (n=34)	Chromophobe carcinoma (n=14)	Sarcomatoid carcinoma (n=1)	P-value
Age, year					0.347*
Mean ± SD	54.2 ± 14.4	59.1 ± 12.0	55.8 ± 16.0	48.0	
Sex					
Male	55 (52.4%)	23 (67.6%)	4 (28.6%)	0 (0%)	0.059#
Female	50 (47.6%)	11 (32.4%)	10 (71.4%)	1 (100%)	
Tumor size, cm					0.022*
Mean ± SD	4.7 ± 2.9	5.9 ± 4.0	7.1 ± 5.3	10	0.022*
Laterality, (n=143)					
Right	50 (51.5%)	12 (37.5%)	4 (30.8%)	1 (100%)	0.215#
Left	47 (48.5%)	20 (62.5%)	9 (69.2%)	0 (0%)	
Lymph node involvement					
Yes	4 (3.8%)	2 (5.9%)	3 (21.4%)	1 (100%)	<0.001#
No	101 (96.2%)	32 (94.1%)	11 (78.6%)	0 (0%)	
Vascular invasion					
Yes	10 (9.5%)	5 (14.7%)	2 (14.3%)	0 (0%)	0.805#
No	95 (90.5%)	29 (85.3%)	12 (85.7%)	1 (100%)	
Capsular invasion, (n=148)					
Yes	29 (29%)	14 (42.4%)	14 (100%)	1 (100%)	<0.001#
No	71 (71%)	19 (57.6%)	0 (0%)	0 (0%)	

^{*} One-Way ANOVA test. # Chi-Square test

The mean tumor size (±SD) was 5.2 (±3.4) cm with minimum and maximum sizes of 0.2 and 21 cm, respectively. Of the 172 renal tumors, 89 cases (51.7%) were <5.5cm, 66 cases (38.4%) were between 5.5-10 cm, and 17 cases (9.9%) were >10 cm. The main size range of renal tumors was <5.5cm [Table 1 and Figure 2].

The capsular invasion was observed in 36.7% of cases. The most prevalent capsular invasion was seen in CRCC and SRCC (100%). The characteristics of renal cell carcinoma subtypes are compared in Table 2.




Figure 2 Prevalence of renal tumor patients based on age and tumor size

4. DISCUSSION

Renal cancer is the 16th cause of cancer death globally. The frequency of renal tumor is substantially different worldwide and is specifically increasing in most developed countries (Motzer et al., 2017). There are studies indicating that the frequency of renal tumors is higher in the developed than the developing countries. In addition, renal tumors are one of the most common urological cancers in Asia and Iran (Chow et al., 2010; Akbari et al., 2008; Reddy et al., 2012). The frequency of RCC is different in various geographical areas of the world. It seems detailed histopathologic evaluation of RCC cases is essential for the prognosis and management of the disease. Therefore, we proposed to explore the epidemiological and clinicopathological features of renal cancers in a Kurdish population in the west of Iran. The most significant risk factors for RCC include obesity, hypertension, smoking, diabetes mellitus, and exposure to occupational carcinogens (Moore et al., 2005; Benichou et al., 1998).

In the current study, clear cell RCC (61%) and PRCC (19.7%) were the most frequent tumors in the patients. RCC was the most common type of renal cancer, which is consistent with the results of other studies around the world (Znaor et al., 2015). According to the reports, South America, Africa, and Southeast Asian countries have the lowest frequency of RCC compared to African Americans and Caucasians (Chow et al., 2010). The high frequency of RCC was detected in Europe, North America and Australia (Chow et al., 2010). On the other hand, the results of the present study showed a slow increase in the frequency of RCC during the study period.

In this study, the frequency of renal tumors was also higher in males than in females. It is in agreement with the findings of other studies done in Iran and other countries (Akbari et al., 2008; Mirzaei et al., 2015; Wong et al., 2017). Higher incidence maybe due to the fact that men are more commonly exposed to the risk factors of cancer than women. The mean age of the individuals with renal tumors was 54.3 years, which is consistent with the results of studies conducted in Pakistan and Malaysia from among the Asian countries (Singam et al., 2010; Hashmi et al., 2014). Table 3 compares the mean age and percentage of the histological subtypes of renal tumors among India, Pakistan, Lebanon and Iran (Reddy et al., 2012; Hashmi et al., 2014; Khafaja et al., 2015; Srivastava et al., 2004). It is interesting that the prevalence of RCC in our population was 89.5%, which is higher than the valued reported by the other studies (Srivastava et al., 2004). Further, the frequency rates of renal tumors detected in CCRCC, PRCC, and CRCC were almost equal to the results of studies in Pakistan, Lebanon and India (Hashmi et al., 2014; Khafaja et al., 2015; Srivastava et al., 2004). However, a study done in India in 2018 showed a frequency of 4.7% for PRCC, which is very lower than that of our study and those of the other studies mentioned above (Srivastava et al., 2004). The mean tumor size in the present study was 5.2 cm. Studies carried out in Pakistan and India showed the mean tumor sizes of 7.2cm and 9.2cm, respectively (Hashmi et al., 2014; Khafaja et al., 2015; Srivastava et al., 2004). Yet, it seems studies have shown a stable reduction in tumor size in the west (Cheng et al., 2009; Kane et al., 2008).

Table 3 The results of Asian studies about primary renal tumor patients (n=5)

Country, a	Mean	Histological type, n								
	age, year	RCC	CCRCC	PRCC	CRCC	SRCC	Oncocytoma carcinoma	Squamous cell carcinoma	Wilm's tumor	References
India, 2018	-	75.2	90.6	4.7	NA	NA	NA	1.8	8.8	(14)
Lebanon, 2015	62.4	71	59.1	22.7	11.4	NA	NA	NA	NA	(21)
Pakistan, 2014	56.4	78	62	24	6	8	1.6	1.6	NA	(20)
India, 2004	55.7	NA	64.02	27	7.86	NA	NA	NA	NA	(22)
The present study	54.3	89.5	61	19.7	8.2	0.6	5.8	1.2	1.2	-

Abbreviation: NA, not available; CCRCC, clear cell renal cell carcinoma; PRCC, papillary renal cell carcinoma; CRCC, chromophobe renal cell carcinoma; SRCC, sarcomatoid renal cell carcinoma.



Capsular invasion is a prognostic factor of localized RCC. In the present study, the prevalence of capsular invasion was 36.7%, which was almost similar to the reports of other studies (Süer et al., 2008; Cho et al., 2009; Jeong et al., 2006) reported the frequency of renal capsular invasion was 35.5%, which had a statistically significant relationship with age, tumor size, stage, and microvascular invasion.

5. CONCLUSION

There were differences in the prevalence of renal cancers around the world based on the results of this study and other studies mentioned above. This may be owing to differences in the distribution of risk factors, socioeconomic levels, early detection, and treatment availability. On the other hand, different environmental and genetic factors are involved in the frequency of cancer and the management of the disease. It is necessary to perform etiological studies to examine the risk factors associated with renal cancer in this region.

Acknowledgment

The authors would like acknowledge Vice-Chancellor for Research and Technology, Kermanshah University of Medical Sciences and the Clinical Research Development Center of Imam Reza Hospital in Kermanshah.

Financial support and sponsorship

The authors gratefully acknowledge the Research Council of Kermanshah University of Medical Sciences (Grant Number: 96461) for financial support.

Authors' Contributions

Babak Izadi & Mazaher Ramezani: designing the study and carrying out experimental research. Mazaher Ramezani: preparation of the article for printing. Somayeh Jalilian & Sedigheh Khazaei: collecting the data. *Masoud Sadeghi: Editing the article and* analysis of the data. *All authors* approved and revised the final version of the article.

Conflict of interest

The authors do not have any conflict of interest to be declared in the present study.

Abbreviations

RCC: Renal cell carcinoma

CCRCC: Clear cell renal cell carcinoma PRCC: Papillary renal cell carcinoma CRCC: Chromophobe renal cell carcinoma

SRCC: Sarcomatoid renal cell carcinoma

NCCN: National Comprehensive Cancer Network

REFERENCE

- 1. Akbari ME, Hosseini SJ, Rezaee A, et al. Incidence of genitourinary cancers in the Islamic Republic of Iran: a survey in 2005. Asian Pac J Cancer Prev 2008; 9:549-52.
- BenichouJ, Chow W-H, McLaughlin JK, et al. Population attributable risk of renal cell cancer in Minnesota. Am J Epidemiol 1998; 148:424-30.
- Cheng L, Zhang S, MacLennan GT, et al. Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol 2009; 40:10-29.
- Cho H-J, Kim SJ, Ha U-S, et al. Prognostic value of capsular invasion for localized clear-cell renal cell carcinoma. Eur Urol 2009; 56:1006-12.

- 5. Chow W-H, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J 2008; 14:288-301.
- 6. Chow W-H, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010; 7:245.
- Czene K, Hemminki K. Familial papillary renal cell tumors and subsequent cancers: a nationwide epidemiological study from Sweden. J Urol 2003; 169:1271-5.
- 8. Eble JN, Sauter G, Epstein JI, et al. Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classi. 2004.
- Hashmi AA, Ali R, Hussain ZF, et al. Clinicopathologic patterns of adult renal tumors in Pakistan. Asian Pac J Cancer Prev 2014; 15:2303-7.

- 10. Jeong IG, Jeong CW, Hong SK, et al. Prognostic implication of capsular invasion without perinephric fat infiltration in localized renal cell carcinoma. Urology 2006; 67:709-12.
- 11. Kane CJ, Mallin K, Ritchey J, et al. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer 2008; 113:78-83.
- 12. Khafaja S, Kourie HR, Matar D, et al. Kidney cancer in Lebanon: a specific histological distribution. Asian Pac J Cancer Prev 2015; 16:363-5.
- 13. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol 2003; 170:2163-72.
- 14. Mirzaei M, Pournamdar Z, Salehiniya H. Epidemiology and trends in incidence ofkidney cancer in Iran. Asian Pac J Cancer Prev 2015; 16:5859-61.
- 15. Moch H, editor. An overview of renal cell cancer: pathology and genetics. Seminars in cancer biology; 2013: Elsevier.
- 16. Moore LE, Wilson RT, Campleman SL. Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: a review. Cancer Invest 2005; 23:240-55.
- 17. Motzer RJ, Jonasch E, Agarwal N, et al. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017;15:804-34.
- 18. Reddy NB, Reddy KN, Madithati P, et al. A study of the epidemiologic distribution of renal tumors in Tirupati, Andhra Pradesh. J NTR Univ Health Sci 2012; 1:217-21.
- 19. Sanfilippo KM, Mc Tique KM, Fidler CJ, et al. Hypertension and obesity and the risk of kidney cancer in 2 large cohorts of US men and women. Hypertension 2014; 63:934-41.
- 20. Setiawan VW, Stram DO, Nomura AM, et al. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol 2007; 166:932-40.
- 21. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30.
- 22. Singam P, Ho C, Hong GE, et al. Clinical characteristics of renal cancer in Malaysia: a ten year review. Asian Pac J Cancer Prev 2010; 11:503-6.
- 23. Srivastava A, Mandhani A, Kapoor R, et al. Prognostic factors in patients with renal cell carcinoma: Is TNM (1997) staging relevant in Indian subpopulation?. Indian J Cancer 2004; 41:99-103.
- 24. Süer E, Ergün G, Baltacı S, et al. Does renal capsular invasion have any prognostic value in localized renal cell carcinoma? J Urol 2008; 180:68-71.
- 25. Wong MC, Goggins WB, Yip BH, et al. Incidence and mortality of kidney cancer: temporal patterns and global trends in 39 countries. Sci Rep 2017; 7:15698.
- 26. Znaor A, Lortet-Tieulent J, Laversanne M, et al. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol 2015; 67:519-30.